Formulation of New Prostate Cancer Molecule, GMC1, for Pre-clinical Studies: Application to Pharmacokinetic Studies
- At: 2016 FIP Congress in Buenos Aires (Argentina)
- Type: Poster
- By: EKPENYONG, Oscar (Texas Southern University, Pharmaceutical Sciences, Houston, United States)
- Co-author(s): Oscar Ekpenyong:|Marc Cox:Biological Sciences,University of El Paso,El Paso,United States|Huan Xie:Pharmaceutical Sciences,Texas Southern University,Houston,United States
GMC1 directly inhibits FKBP52, a positive regulator of androgen (AR), glucocorticoid, and progesterone receptors activities, making it an attractive for the treatment of castration-resistant prostate cancer.
We developed and validated an LC/MS/MS method for the quantification of GMC1 in solution, plasma and urine; determined the stability, log P,.. The access to the whole abstract and the presentation file is available to FIP members and to congress participants of that specific congress.